Patient’s quality of life

Treatments targeting inflammation of the central nervous system may potentially lead to increased risk of serious side effects, possibly due to systemic immune suppression. It is anticipated that the N2B-patch drug-device combination will utilise an extended controlled release profile and the prolonged release of the Active Pharmaceutical Ingredient from the multifunctional galenic formulation. Consequentially, this should reduce the number of required applications and therefore reduce patient intervention. N2B-patch has been established on the basis on user requirements so these parameters are fundamentally important to the design space specifications.